Oncologist Puglisi: “Ribociclib therapy for breast cancer is safe and well tolerated”

Fabio Puglisi, director of the Department of Medical Oncology at the Irccs CRO in Aviano, ‘The data from the Phase III Natalee study show that adjuvant therapy reduces the risk of relapses by 25%. Moreover, it is safe and preserves a good quality of life for patients’